Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity
Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
Expansion of leading biomarker and bioanalysis company enhances bioanalytical solutions for targeted radiopharmaceuticals
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
TPE tubing from Freudenberg also offers many different sterilization options including autoclave, gamma irradiation, x-ray, and e-beam
A total of three targets have been selected for portfolio entry in the collaboration to date, with the potential to generate further future development milestones and sales-based royalty revenues for BenevolentAI
This new fund is amongst the largest for the sector in India
Multiples is the first private equity (PE) investor in the company
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
Subscribe To Our Newsletter & Stay Updated
